Verrica Pharmaceuticals Inc. (VRCA) Stock Analysis
A live, multi-source view of Verrica Pharmaceuticals Inc. (VRCA): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Sector: Healthcare · Industry: Biotechnology · United States · 76 employees · verrica.com
Key statistics · as of 2026-09-06
As of 2026-09-06, Verrica Pharmaceuticals Inc. (VRCA) had a market capitalization of $91.0M (forward -3.6) and a beta of 1.50; the shares traded in a 52-week range of $3.28 – $9.82 (4.7% over the year).
- Market cap
- $91.0M
- Enterprise value
- $81.7M
- Forward P/E
- -3.6
- Price / book
- 21.12
- EPS (trailing)
- $-1.74
- EPS (forward)
- $-1.48
- Payout ratio
- 0.0%
- 52-week range
- $3.28 – $9.82
- 52-week change
- 4.7%
- Beta
- 1.50
- Average volume
- 60,984
- Shares outstanding
- 17.2M
- Short % of float
- 3.05%
- Profit margin
- -102.8%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-10
In RapidTradeView’s 2026-09-10 scan of the US universe, Verrica Pharmaceuticals Inc. (VRCA) last closed at $5.06 (the last completed close before that scan).
Technicals at the scan: RSI 46 (neutral territory), price -0.6% versus its 20-day average, 20-day versus 50-day average spread -5.9%, MACD histogram 0.04.
Sentiment inputs: StockTwits 71% bullish; analyst consensus score 71/100.
Next scheduled company event: in 64 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
Members of Congress disclosed 0 buys and 0 sells of VRCA; corporate insiders filed 6 buys and 0 sells (4 distinct filers, latest disclosure 2026-08-18). Filings arrive days to weeks after the trade and are not a live signal. Most active filers: Jayson Rieger (2B/0S), Noah L. Rosenberg (2B/0S), John J. Kirby (1B/0S), David Zawitz (1B/0S). Who is trading what
RapidTradeView pick record
VRCA has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls Verrica Pharmaceuticals Inc. (VRCA) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell VRCA.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.